Biologic anti-IL17 drugs in erythrodermic psoriasis

Abstract

BackgroundErythrodermic psoriasis (EP) is a potentially life-threatening disease, and there is currently no consensus regarding its optimal treatment. Biological drugs approved for Psoriasis Vulgaris treatment have been used as alternatives to traditional medications. ObjectiveTo evaluate the clinical response and tolerability of anti-IL17 biologic drugs during a 2-year-follow-up. MethodsThis was a retrospective prospective study. EP cases, defined as >75% body surface area involvement, in patients ≥18 years old treated with anti-IL17 for at least six consecutive months were enrolled and then followed until 104 weeks. Patient characteristics, overall clinical responses, PASI score changes, and adverse events were analyzed. ResultsSixteen patients met the criteria, of which 50% had achieved the PASI 100 response at week 12 and in 93.7% at week 24. In the prospective observation of the cohort, 87.5% were still in remission at week 52 and 81.25% at 104 weeks, without adverse events. The three patients in whom the treatment was interrupted lost efficacy and were switched to other therapies. LimitationsOnly descriptive analysis was conducted due to the limited number of patients. ConclusionsA satisfactory long-term clinical response without adverse effects was observed in this case series, suggesting the interest of anti-IL17 in EP treatment.